2024
Researching COVID to enhance recovery (RECOVER) pediatric study protocol: Rationale, objectives and design
Gross R, Thaweethai T, Rosenzweig E, Chan J, Chibnik L, Cicek M, Elliott A, Flaherman V, Foulkes A, Witvliet M, Gallagher R, Gennaro M, Jernigan T, Karlson E, Katz S, Kinser P, Kleinman L, Lamendola-Essel M, Milner J, Mohandas S, Mudumbi P, Newburger J, Rhee K, Salisbury A, Snowden J, Stein C, Stockwell M, Tantisira K, Thomason M, Truong D, Warburton D, Wood J, Ahmed S, Akerlundh A, Alshawabkeh A, Anderson B, Aschner J, Atz A, Aupperle R, Baker F, Balaraman V, Banerjee D, Barch D, Baskin-Sommers A, Bhuiyan, Bind M, Bogie A, Bradford T, Buchbinder N, Bueler E, Bükülmez H, Casey B, Chang L, Chrisant M, Clark D, Clifton R, Clouser K, Cottrell L, Cowan K, D’Sa V, Dapretto M, Dasgupta S, Dehority W, Dionne A, Dummer K, Elias M, Esquenazi-Karonika S, Evans D, Faustino E, Fiks A, Forsha D, Foxe J, Friedman N, Fry G, Gaur S, Gee D, Gray K, Handler S, Harahsheh A, Hasbani K, Heath A, Hebson C, Heitzeg M, Hester C, Hill S, Hobart-Porter L, Hong T, Horowitz C, Hsia D, Huentelman M, Hummel K, Irby K, Jacobus J, Jacoby V, Jone P, Kaelber D, Kasmarcak T, Kluko M, Kosut J, Laird A, Landeo-Gutierrez J, Lang S, Larson C, Lim P, Lisdahl K, McCrindle B, McCulloh R, McHugh K, Mendelsohn A, Metz T, Miller J, Mitchell E, Morgan L, Müller-Oehring E, Nahin E, Neale M, Ness-Cochinwala M, Nolan S, Oliveira C, Osakwe O, Oster M, Payne R, Portman M, Raissy H, Randall I, Rao S, Reeder H, Rosas J, Russell M, Sabati A, Sanil Y, Sato A, Schechter M, Selvarangan R, Tejtel S, Shakti D, Sharma K, Squeglia L, Srivastava S, Stevenson M, Szmuszkovicz J, Talavera-Barber M, Teufel R, Thacker D, Trachtenberg F, Udosen M, Warner M, Watson S, Werzberger A, Weyer J, Wood M, Yin H, Zempsky W, Zimmerman E, Dreyer B, Consortium O. Researching COVID to enhance recovery (RECOVER) pediatric study protocol: Rationale, objectives and design. PLOS ONE 2024, 19: e0285635. PMID: 38713673, PMCID: PMC11075869, DOI: 10.1371/journal.pone.0285635.Peer-Reviewed Original ResearchConceptsYoung adultsClinical courseAdolescent Brain Cognitive DevelopmentCaregiver-child pairsLong-term outcomesObservational cohort studyOutcomes of COVID-19De novo cohortAdolescent Brain Cognitive Development StudySociodemographic correlatesCommunity partnersBaseline assessmentLongitudinal follow-upPotential therapeutic interventionsPediatric protocolsCohort studyCollaborative partnershipsProspective cohortFollow-upStudy protocolFederal partnersNIH Researching COVIDLong-term outcomes of COVID-19Enhanced recoveryData collectionGuidance for prevention and management of COVID-19 in children and adolescents: A consensus statement from the Pediatric Infectious Diseases Society Pediatric COVID-19 Therapies Taskforce
Willis Z, Oliveira C, Abzug M, Anosike B, Ardura M, Bio L, Boguniewicz J, Chiotos K, Downes K, Grapentine S, Hersh A, Heston S, Hijano D, Huskins W, James S, Jones S, Lockowitz C, Lloyd E, MacBrayne C, Maron G, McDonough M, Miller C, Morton T, Olivero R, Orscheln R, Schwenk H, Singh P, Soma V, Sue P, Vora S, Nakamura M, Wolf J. Guidance for prevention and management of COVID-19 in children and adolescents: A consensus statement from the Pediatric Infectious Diseases Society Pediatric COVID-19 Therapies Taskforce. Journal Of The Pediatric Infectious Diseases Society 2024, 13: 159-185. PMID: 38339996, PMCID: PMC11494238, DOI: 10.1093/jpids/piad116.Peer-Reviewed Original ResearchConceptsRisk factorsRisk stratificationPediatric intensive care medicineEffects of therapyNon-hospitalized childrenPediatric infectious diseasesSevere COVID-19Cases of infectionMeta-analysis of dataIntensive care medicineClinical characteristicsPreventive therapyPediatric populationManagement of COVID-19Fatal infectionConsensus statementSevere illnessTherapyMeta-analysisTherapeutic interventionsSARS-CoV-2Expert consensusCare medicineRe-convenedGuidance statements
2023
Human Papillomavirus Vaccination Status and Correlates Among Mid-Adult Women: Connecticut, USA, 2016–2019
Sheth S, Johnson N, Sullivan E, Torres A, Oliveira C, Niccolai L. Human Papillomavirus Vaccination Status and Correlates Among Mid-Adult Women: Connecticut, USA, 2016–2019. Journal Of Women's Health 2023, 33: 28-32. PMID: 37943625, PMCID: PMC10794823, DOI: 10.1089/jwh.2022.0456.Peer-Reviewed Original ResearchConceptsMid-adult womenVaccination statusHPV vaccinationHPV vaccineHuman Papillomavirus Vaccination StatusHPV vaccination statusHuman papillomavirus vaccinationAge 26 yearsHealth care providersCross-sectional surveyPapillomavirus vaccinationUnvaccinated womenVaccinated womenVaccine informationCare providersVaccinationAdult womenVaccineWomenBehavioral correlatesCorrelatesStatusPotential benefitsYearsParticipants
2022
Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents
Wolf J, Abzug MJ, Anosike BI, Vora SB, Waghmare A, Sue PK, Olivero RM, Oliveira CR, James SH, Morton TH, Maron GM, Young JL, Orscheln RC, Schwenk HT, Bio LL, Willis ZI, Lloyd EC, Hersh AL, Huskins CW, Soma VL, Ratner AJ, Hayes M, Downes K, Chiotos K, Grapentine SP, Wattier RL, Lamb GS, Zachariah P, Nakamura MM. Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents. Journal Of The Pediatric Infectious Diseases Society 2022, 11: 177-185. PMID: 35107571, PMCID: PMC8903349, DOI: 10.1093/jpids/piab124.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMonoclonal antibody therapyPediatric infectious diseasesAntibody therapyEmergency use authorizationSevere diseasePostexposure prophylaxisHigh riskCOVID-19Severe acute respiratory syndrome coronavirus 2Certain high-risk conditionsSpecific monoclonal antibody therapyAcute respiratory syndrome coronavirus 2Infectious diseasesRespiratory syndrome coronavirus 2Moderate COVID-19Pediatric critical care medicineSyndrome coronavirus 2Coronavirus disease 2019Critical care medicineHigh-risk conditionsSeries of teleconferencesHigh-risk exposureBamlanivimab monotherapyInfusion reactionsControlled Trials
2021
Patterns of recommended vaccine receipt among women ages 24–45 years: a cross-sectional analysis
Ellingson MK, Oliveira CR, Sheth SS, Sullivan EL, Torres A, Shapiro ED, Niccolai LM. Patterns of recommended vaccine receipt among women ages 24–45 years: a cross-sectional analysis. BMC Public Health 2021, 21: 1283. PMID: 34193100, PMCID: PMC8247221, DOI: 10.1186/s12889-021-11340-4.Peer-Reviewed Original ResearchConceptsMid-adult womenVaccine receiptCross-sectional analysisHPV vaccineOngoing case-control studyReceipt of influenzaHealth care visitsCase-control studyWomen ages 24Quarter of adultsLogistic regression analysisCare visitsIndividual vaccinesHealthcare utilizationMultiple vaccinesVaccineAge 24White womenWomenDemographic characteristicsRegression analysisLower ratesInfluenzaReceiptPast yearInpatient Immunization With HPV Vaccine: A Qualitative Study With Postpartum Women
Avni-Singer L, Oliveira CR, Torres A, Shapiro ED, Niccolai LM, Sheth SS. Inpatient Immunization With HPV Vaccine: A Qualitative Study With Postpartum Women. Women's Health Issues 2021, 31: 384-391. PMID: 33715924, PMCID: PMC8260440, DOI: 10.1016/j.whi.2021.02.002.Peer-Reviewed Original ResearchConceptsHPV vaccinePostpartum womenPatient-centered approachHPV immunization programHuman papillomavirus vaccineRates of immunizationIterative thematic approachYoung adult femalesInpatient immunizationHospital dischargePapillomavirus vaccinePostpartum patientsMedian ageImmunization programsPatient's perspectiveProgram implementationVaccine hesitancyImmunizationVaccineWomenQualitative studyThematic approachPatientsHospitalAdult females
2020
Evaluation of an Inpatient Postpartum Human Papillomavirus Immunization Program.
Avni-Singer L, Oliveira CR, Torres A, Shapiro ED, Niccolai LM, Sheth SS. Evaluation of an Inpatient Postpartum Human Papillomavirus Immunization Program. Obstetrics And Gynecology 2020, 136: 1006-1015. PMID: 33030866, PMCID: PMC7584732, DOI: 10.1097/aog.0000000000004097.Peer-Reviewed Original ResearchConceptsHPV immunization programImmunization programsHPV vaccinePostpartum womenHuman papillomavirus immunization programmesLow-income patient populationCharacteristics of patientsRates of immunizationHospital-based obstetricsProportion of womenChi-squared testEligible visitsOutpatient doseOutpatient dosesHospital stayVaccine seriesCohort studyHospital dischargeGynecology clinicVaccine uptakePatient populationAdditional dosesSubsequent doseLogistic regressionDoseTrends in Anogenital Wart Diagnoses in Connecticut, 2013-2017
Yakely AE, Niccolai LM, Oliveira CR. Trends in Anogenital Wart Diagnoses in Connecticut, 2013-2017. JAMA Network Open 2020, 3: e1920168. PMID: 32003814, PMCID: PMC7042856, DOI: 10.1001/jamanetworkopen.2019.20168.Peer-Reviewed Original Research
2018
Impact of a clinical interventions bundle on uptake of HPV vaccine at an OB/GYN clinic
Deshmukh U, Oliveira CR, Griggs S, Coleman E, Avni-Singer L, Pathy S, Shapiro ED, Sheth SS. Impact of a clinical interventions bundle on uptake of HPV vaccine at an OB/GYN clinic. Vaccine 2018, 36: 3599-3605. PMID: 29759380, PMCID: PMC6314176, DOI: 10.1016/j.vaccine.2018.05.039.Peer-Reviewed Original ResearchConceptsIntervention bundleOB/GYN clinicPrevalence of womenUninsured womenVaccine uptakeAttributable reductionsMissed opportunityHPV vaccine seriesVaccine-eligible visitsVaccine-eligible womenHPV vaccine uptakeMonthly rateYoung adult womenLast study monthInterrupted time series modelHPV vaccineVaccine seriesMedical recordsHispanic womenAdult womenWhite womenStudy periodYoung adultsVaccineWomen
2017
Missed opportunities for HPV immunization among young adult women
Oliveira CR, Rock RM, Shapiro ED, Xu X, Lundsberg L, Zhang LB, Gariepy A, Illuzzi JL, Sheth SS. Missed opportunities for HPV immunization among young adult women. American Journal Of Obstetrics And Gynecology 2017, 218: 326.e1-326.e7. PMID: 29223597, PMCID: PMC5924702, DOI: 10.1016/j.ajog.2017.11.602.Peer-Reviewed Original ResearchConceptsHuman papillomavirus immunizationYoung adult womenGynecology clinicAdult womenMissed clinical opportunitiesVaccine-eligible visitsVaccine-eligible womenHuman papillomavirus vaccineMultivariable logistic regressionCross-sectional studyHospital-based obstetricsYears of ageYoung adult populationSignificant racial disparitiesUrban obstetricsPostpartum visitClinic visitsEligible womenPapillomavirus vaccinePatient characteristicsHPV immunizationHuman papillomavirusAdjusted oddsMedical recordsDifferent vaccines
2016
Influenza-like illness in an urban community of Salvador, Brazil: incidence, seasonality and risk factors
Oliveira CR, Costa GSR, Paploski IAD, Kikuti M, Kasper AM, Silva MMO, Tavares AS, Cruz JS, Queiroz TL, Lima HCAV, Calcagno J, Reis MG, Weinberger DM, Shapiro ED, Ko AI, Ribeiro GS. Influenza-like illness in an urban community of Salvador, Brazil: incidence, seasonality and risk factors. BMC Infectious Diseases 2016, 16: 125. PMID: 26975185, PMCID: PMC4791800, DOI: 10.1186/s12879-016-1456-8.Peer-Reviewed Original ResearchConceptsInfluenza-like illnessYears of ageAcute febrile illnessAnnual incidenceRisk of ILIChildren 5Year oldsIncidence of ILIMean annual incidenceEpidemiology of influenzaCommunity-based surveillanceNegative test resultsSeasonal influenza transmissionILI peakMethodsBetween 2009Febrile illnessSore throatRegression modelsDisease burdenRisk factorsSchool-aged childrenEmergency unitInfluenza transmissionSignificant burdenYoung school-age children